Aclaris Therapeutics Inc (ACRS) Stock Analysis
Verdict: WATCH (do not buy)
Severe operational cash burn ($19.8M/quarter) threatens pipeline momentum for ATI-052/2138, making dilution a key 12-month swing risk.
Investment score: 41/100
Analysis as of
Is Aclaris Therapeutics Inc stock worth reviewing? AI model thesis
The model score of 41/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 25/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 60/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Aclaris Therapeutics Inc opportunities and risks
What speaks for ACRS
- Upcoming Phase 1b proof-of-concept trial readouts for lead bispecific antibody ATI-052.
What speaks against ACRS
- Heavy quarterly cash burn rates accelerating dilution risk.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ACRS | n/a | 76.3x | n/a | 95.6% | -921.5% | -9.9% |
| SGP | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.8% |
| LXRX | n/a | 19.7x | n/a | 98.9% | -147.4% | -9.8% |
| COLL | 14.6x | 0.9x | 2.5x | 60.0% | 5.9% | 45.4% |
| CRMD | 3.1x | 1.3x | 1.9x | 82.8% | 40.5% | 43.4% |
| Peer median | n/a | 1.1x | n/a | 71.4% | 3.0% | 18.8% |
Frequently asked questions about Aclaris Therapeutics Inc (ACRS)
Is ACRS stock a good investment?
The cached TradeMates AI model rates Aclaris Therapeutics Inc as WATCH (do not buy) with an investment score of 41/100. The model score of 41/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Is ACRS stock a buy?
The TradeMates model verdict for ACRS is WATCH (do not buy) with an investment score of 41/100. Treat this as a model signal to review, not a personal buy recommendation.